Company Profile

Shenzhen Main Luck Pharmaceuticals Inc. is the capital convergent union from China (Shenzhen Pharmaceuticals Factory), Japan (Mercian Business Corp.) and Hongkong (Main Life Co., Ltd). Keeping pace with the developing of top technology in medical and pharmaceutical field and regarding creativeness and high efficiency as the company's expanding motivation, it has been keeping 30% increasing rate annually since the foundation in 1990. Based on the integratively ranking the second among anti-tumor producers in China, it has become a leading enterprise in this field and has been creating an international pharmaceuticals company.

As one of the earliest manufactory of anti-tumor medicine, Main Luck Pharmaceuticals sticks to the ever-changing demands of the market. Not only has it introduced the Japanese GMP management mode to establish the quality management system, but has also imported advanced manufacturing and testing equipment from USA, Netherland, Japan, Switzerland and Germany to set up a perfect quality control system as well as a quality-testing center. Because of this, Main Luck Pharmaceuticals Inc. was among the first to have received the Chinese GMP certification.

At present, Main Luck Pharmaceuticals has provided state-rated new products such as Pirarubicin, Aclarubicin, Doxorubicin, Daunorubicin, Docetaxel, Vincristin, Bleomycin, Lastet, Mesna, Isophosphamide. It holds the production capacity of 5 million doses of lyophilized injection, 50 million doses of injection or 10 million capsules. It possesses the industry chains for making raw materials with advanced technology standards.

Based on wildly and solid cooperation with top national and international research institutes, such as China Academy of Science (Shanghai) Medicament Graduate School, Sichuan Antibiotic Industry Graduate School, National Medicament Preparation Engineering Research Center, Pharmacy Engineering Graduate School of Singapore National University, USA Vanderbilt University, Japan Kumamoto University, and some internationally famous company like Japan Nippon Kayaku Co., Ltd., comprehensive communications and exchanges have been built up. Striving to incessantly improve and promote the leading products, Main Luck Pharmaceuticals continuously develop new drug using biological genetic engineering techniques, anti-tumor accessory medication and moving up to a new field. We devote to develop novel highly-technological drugs that are becoming leader among the world like anti-CD20 single clone antibody, CM101 which prevents tumor blood vessel from reproducing. Meanwhile, it explores new preparation areas and builds up the top technology platform such as sustained release micro-sphere for injection, liposome and colon-specific release updated. Main Luck Pharmaceuticals has already rapidly advanced to various product-researching fields from a single product-producing one.

In current world, information instantly changes moment by moment. Based on our principle "Insistently promoting Human Health and contributing in Health Care development" Main Luck Pharmaceuticals has built up a service network with fine academic performance, covering 29 provinces, cities, municipalities in the country and has constructed the communicative bridge and string between the company and customers. It often organizes and participates national and international faculty professional conference, intercommunication and community or public health care popularity to bring in and introduce new technology and knowledge. It shakes hands with inland or overseas tumor specialists to undertake strict multi-center clinic science researches; breaks through and solves the frontier medical subjects. Meanwhile it enhances intercourse and exchange with important academic periodicals and shares the production in modern medical treatment and research. All kinds of the built platforms effectively facilitate the development of medical level. With the increasing of sales in inland, high quality products are also widely recognized internationally. At present, products from Main Luck have been exported to Mid-East, South Asia, South America, East Europe and so on.

Keeping efficient exploration and operation of the resources, combining service to society with creation of enterprise value, conforming world resources, expanding enterprise development, capturing vast quantity of professional talents, mastering pharmaceuticals development frontier, and depending on internationally leading research resources and specialized faculty sales network are the core of competitive strength for Main Luck to conquer the market.

Abundant and solid accumulation and highly efficient incorporative team have brought wider and steadier cooperation with multiple world famous academic facility and industry, which are the cornerstone for our company leading the head of pharmaceutical technology.

Cooperation motivates power for developing and mutual share builds up starting point for success. With a goal to promote national pharmaceuticals and the spirit to be highly responsible for life, Main Luck Pharmaceuticals builds up strong platform to effectively conform resources. With strictly following international professional trends, actively exploring into new product research in high and advanced top fields, deepen enterprise core specially at a high Main Luck speed, keeping enterprise's strategy, ability and industry in leading position, widely absorbing deep cooperation all over the world, designing the favorable career for staffs, offering chances of mutual development for participators, striving for company incessant increase and ever lasting success, Main Luck Pharmaceuticals is becoming an internationally comprehensive industry stock-owned group.

Care for life, Care for health and care for Main Luck Pharmaceuticals.